Related Experiment Videos
Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms
F J Jimenez1, J L Burchette, J M Grichnik
1Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
Summary
Ber-EP4 antibody staining is broader than previously known, appearing in various skin lesions beyond basal cell carcinoma. This finding expands the diagnostic utility of Ber-EP4 in identifying proliferative epithelial and adnexal tumors.
Area of Science:
- Dermatopathology
- Immunohistochemistry
- Oncology
Background:
- Ber-EP4 antibody targets a cell membrane glycoprotein with an undefined function.
- Distinguishing basal cell carcinoma from squamous cell carcinoma is a key dermatological challenge.
- Previous studies reported Ber-EP4 immunoreactivity in specific skin epithelia and tumors.
Purpose of the Study:
- To further characterize the immunoreactivity of Ber-EP4 in various proliferative epithelial skin lesions.
- To investigate the diagnostic potential of Ber-EP4 beyond basal cell carcinoma.
Main Methods:
- Examined 76 formalin-fixed, paraffin-embedded proliferative epithelial skin lesions.
- Utilized hematoxylin and eosin staining alongside Ber-EP4 immunostaining.
- Analyzed fetal skin sections and frozen skin sections from Mohs surgery.
Main Results:
- Ber-EP4 staining observed in vellus hair follicle epithelium and sweat gland secretory coils in paraffin sections.
- Anagen terminal follicle epithelium and sweat ducts showed negative staining in paraffin sections.
- Additional staining in eccrine ducts and terminal follicle structures noted in frozen sections.
- Positive staining also seen in trichoepitheliomas, dermatofibromas, mammary Paget's disease, and neoplasms with adnexal differentiation.
Conclusions:
- Ber-EP4 immunoreactivity extends to a variety of proliferative epidermal and adnexal lesions, not exclusively basal cell carcinoma.
- These findings suggest a broader diagnostic application for Ber-EP4 in skin lesion characterization.